StreetInsider.com News Articles

Leerink highlights drug demand rebound after Memorial Day

Fri, 12 Jun 2026 14:42:02 -0400

Investing.com - Leerink reported prescription drug trends for the week ending June 5 showed a rebound following Memorial Day weekend, with the total U.S. drug market posting week-over-week growth of 10% compared to the prior week's decline of 8%.

Tirzepatide, sold as Mounjaro and Zepbound, recorded year-over-year prescription growth of 46% for the one-week period, 51% for four weeks, and 57% for 12 weeks. Semaglutide, marketed as Ozempic and Wegovy, showed year-over-year prescription growth of 22% for one week, 21% for four weeks, and 18% for 12 weeks. The total Wegovy franchise, including injectable and oral formulations, increased 10% week-over-week, while

Leerink highlights drug demand rebound after Memorial Day

Fri, 12 Jun 2026 14:42:02 -0400

Leerink highlights drug demand rebound after Memorial Day

Fri, 12 Jun 2026 14:42:02 -0400

Leerink highlights drug demand rebound after Memorial Day

Fri, 12 Jun 2026 14:42:02 -0400

Leerink highlights drug demand rebound after Memorial Day

Fri, 12 Jun 2026 14:42:02 -0400

Leerink highlights drug demand rebound after Memorial Day

Fri, 12 Jun 2026 14:42:02 -0400

Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory

Thu, 11 Jun 2026 02:01:00 -0400

- Data from pivotal studies of CASGEVY in children ages 5–11 with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrate transformative potential in younger patients, consistent with the durable benefits established in patients 12 years and older -

- Data simultaneously published in the New England Journal of Medicine -

- Regulatory review underway in the United States to expand the use of CASGEVY, and Vertex has recently completed submissions in the Kingdom of Saudi Arabia and United Kingdom -

BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the

Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory

Thu, 11 Jun 2026 02:01:00 -0400

- Data simultaneously published in the New England Journal of Medicine -

- Regulatory review underway in the United States to expand the use of CASGEVY, and Vertex has recently completed submissions in the Kingdom of Saudi Arabia and United Kingdom -

BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the

Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory

Thu, 11 Jun 2026 02:01:00 -0400

- Data simultaneously published in the New England Journal of Medicine -

- Regulatory review underway in the United States to expand the use of CASGEVY, and Vertex has recently completed submissions in the Kingdom of Saudi Arabia and United Kingdom -

BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the

Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory

Thu, 11 Jun 2026 02:01:00 -0400

- Data simultaneously published in the New England Journal of Medicine -

- Regulatory review underway in the United States to expand the use of CASGEVY, and Vertex has recently completed submissions in the Kingdom of Saudi Arabia and United Kingdom -

BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the

Form 4 VERTEX PHARMACEUTICALS For: Jun 05 Filed by: Bozic Carmen

Tue, 09 Jun 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260609/26624049.html

Form 4 VERTEX PHARMACEUTICALS For: Jun 05 Filed by: Bozic Carmen

Tue, 09 Jun 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260609/26624049.html

Form 144 VERTEX PHARMACEUTICALS Filed by: Bozic Carmen

Fri, 05 Jun 2026 14:33:00 -0400

si-local-file:///var/storage/secattach/20260605/26610505.html

Form 144 VERTEX PHARMACEUTICALS Filed by: Bozic Carmen

Fri, 05 Jun 2026 14:33:00 -0400

si-local-file:///var/storage/secattach/20260605/26610505.html

Vertex presents positive data for ALYFTREK in young cystic fibrosis patients

Fri, 05 Jun 2026 12:05:12 -0400

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) presented clinical data showing that 65% of children ages 2 to 5 with cystic fibrosis achieved sweat chloride levels below 30 mmol/L when treated with ALYFTREK, according to data presented at the European Cystic Fibrosis Conference.

The Phase 3 open-label study included 67 children with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes, including those homozygous for the F508del mutation and those with F508del/minimal function mutations. Treatment with ALYFTREK resulted in a mean reduction in sweat chloride of 9.6 mmol/L from baseline through week 24, with 92% of children achieving concentrations below 60 mmol/L.

Vertex plans to submit for global regulatory approvals of

Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference

Fri, 05 Jun 2026 12:00:00 -0400

- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of <30 mmol/L; Vertex on track to initiate global regulatory submissions in first half of 2026 -

- Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older -

- Phase 3 data on TRIKAFTA® in children 1 to <2 years also presented; Vertex has initiated global regulatory submissions -

BOSTON--(BUSINESS WIRE)--

Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference

Fri, 05 Jun 2026 12:00:00 -0400

- Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older -

- Phase 3 data on TRIKAFTA® in children 1 to <2 years also presented; Vertex has initiated global regulatory submissions -

BOSTON--(BUSINESS WIRE)--

Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference

Fri, 05 Jun 2026 12:00:00 -0400

- Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older -

- Phase 3 data on TRIKAFTA® in children 1 to <2 years also presented; Vertex has initiated global regulatory submissions -

BOSTON--(BUSINESS WIRE)--

Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference

Fri, 05 Jun 2026 12:00:00 -0400

- Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older -

- Phase 3 data on TRIKAFTA® in children 1 to <2 years also presented; Vertex has initiated global regulatory submissions -

BOSTON--(BUSINESS WIRE)--

Form 4 VERTEX PHARMACEUTICALS For: Jun 01 Filed by: Liu Joy

Wed, 03 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260603/26598817.html

Form 4 VERTEX PHARMACEUTICALS For: Jun 01 Filed by: Liu Joy

Wed, 03 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260603/26598817.html

Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10

Wed, 03 Jun 2026 16:00:00 -0400

BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in the Goldman Sachs 47th Annual Global Healthcare Conference. Dr. Reshma Kewalramani, President and Chief Executive Officer will participate in a fireside chat on Wednesday, June 10, 2026, at 11:20 a.m. ET.

A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com, in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website.

About Vertex

Vertex is a global biotechnology company that invests in scientific

Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10

Wed, 03 Jun 2026 16:00:00 -0400

About Vertex

Vertex is a global biotechnology company that invests in scientific

Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10

Wed, 03 Jun 2026 16:00:00 -0400

About Vertex

Vertex is a global biotechnology company that invests in scientific

Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10

Wed, 03 Jun 2026 16:00:00 -0400

About Vertex

Vertex is a global biotechnology company that invests in scientific